52,301 results match your criteria Renal Cell Carcinoma


[What is new in the diagnosis and therapy of renal cell carcinoma?]

Dtsch Med Wochenschr 2020 Jun 3;145(11):734-739. Epub 2020 Jun 3.

Medizinische Klinik 2, Hämatologie und Onkologie, Universitätsklinikum der Johann-Wolfgang-Goethe-Universität Frankfurt, Frankfurt am Main.

Renal cell carcinomas (RCC) include different tumor entities, of which clear cell RCC is the most common tumor with approx. 75 % followed by the papillary RCC with 10-15 %. RCC are increasingly being diagnosed incidental in the context of abdominal diagnostics from other indications using sonography or cross-sectional imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0982-4331DOI Listing

Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.

Eur J Med Chem 2020 May 22;200:112482. Epub 2020 May 22.

Faculty of Life Science and Technology, Kunming University of Science and Technology, PR China. Electronic address:

In recent years, there have been increased incidences of metastatic renal cell carcinoma (RCC), which is refractory to conventional chemotherapy. Owing to the insensitivity to traditional therapy, targeted therapy becomes a possible alternative strategy. Over the past decade, the development of targeted treatments for metastatic RCC has advanced considerably. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2020.112482DOI Listing

Nuclear NADPH Oxidase-4 Associated With Disease Progression In Renal Cell Carcinoma.

Transl Res 2020 May 31. Epub 2020 May 31.

Department of Urology, University of Texas Health, San Antonio, TX.

Nuclear NADPH oxidase-4 (Nox4) is a key component of metabolic reprogramming and is often overexpressed in renal cell carcinoma (RCC). However, its prognostic role in RCC remains unclear. Here we examined the significance of nuclear Nox4 on disease progression and development of drug resistance in advanced RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2020.05.009DOI Listing

Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.

PLoS One 2020 3;15(6):e0233887. Epub 2020 Jun 3.

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida, United States of America.

Increased cytoplasmic lipid droplets (LDs) and elevated AKT/mTOR signaling are characteristics of clear cell renal cell carcinoma (ccRCC). Lysophosphatidic acid (LPA), a potent lipid mitogen generated via autotaxin (elevated in ccRCC), can modulate tumor progression but its role in altering chemotherapeutic sensitivity to mTOR inhibitors is unclear and thus is the focus of the studies presented herein. Using malignant (A-498, 769-P and 786-O) and normal immortalized kidney (HK-2) cell lines, we investigated their cellular responsiveness to Temsirolimus (TEMS, mTOR inhibitor) in the absence or presence of LPA by monitoring alterations in AKT/mTOR pathway mediators (via western blotting), LDs (using LipidTOX and real-time PCR to assess transcript changes in modulators of LD biogenesis/turnover), mitochondrial networks (via immunofluorescence staining for TOM20 and TOM70), as well as cellular viability. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233887PLOS

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

J Clin Oncol 2020 Jun 3:JCO1903315. Epub 2020 Jun 3.

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

Purpose: Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.03315DOI Listing

Vismodegib Experience in a Renal Transplant Patient With Basal Cell Carcinoma.

Exp Clin Transplant 2020 Jun 2. Epub 2020 Jun 2.

From the Medical Oncology Department and the 2Transplantation Department, Baskent University, Ankara, Turkey.

The hedgehog inhibitor vismodegib has been tested and suggested as an effective treatment option for cases of locally advanced or metastatic basal cell carcinoma. A 58-year-old female renal transplant patient with recurrent, inoperable basal-cell carcinoma that originated from nasal skin was evaluated by the transplantation counsel. After a multidisciplinary evaluation of the patient, vismodegib at a dose of 150 mg/day was started in February 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.2020.0293DOI Listing

Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma.

Quant Imaging Med Surg 2020 May;10(5):988-998

Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

Background: This study aimed to identify clear cell renal cell carcinoma (ccRCC) histopathological grade and differentiate it from fat-poor angiomyolipoma (AML). This was achieved through contrast-enhanced magnetic resonance (MR) T1 mapping with intravenous low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA).

Methods: In total, 56 consecutive patients received MR scanning between January 2016 and December 2018 using the pre- and post- contrast-enhanced T1 mapping sequences with low-dose Gd-DTPA (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/qims-19-723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242294PMC

Case of renal cell carcinoma associated with synchronous contralateral renal pelvic cancer and bladder cancer.

Urol Case Rep 2020 Sep 19;32:101267. Epub 2020 May 19.

Department of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

Synchronous double primary RCC and TCC of the renal pelvis and bladder are extremely uncommon. Proper management is a medical dilemma, and no standard treatment strategy has been agreed upon for this rare situation. Our case involved a large mass in the right kidney and multiple masses in the left renal pelvis, ureter, and bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260428PMC
September 2020

Metastasis of renal cell carcinoma to the distal ureteral stump beyond recommended baseline surveillance duration.

Urol Case Rep 2020 Sep 19;32:101266. Epub 2020 May 19.

Department of Surgery - Division of Urology, 1 Hospital Drive, MC 301E, Columbia, MO, 65212, USA.

A 71-year-old male with history of clear cell renal cell carcinoma (RCC) 6-years status post nephrectomy presented for gross hematuria. Cystoscopy revealed a bulge of the right ureteral orifice, and transurethral resection confirmed RCC metastasis to the ureteral stump. Ureterectomy with bladder cuff excision was performed, and the patient is currently undergoing aggressive imaging surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256291PMC
September 2020

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma.

Urol Case Rep 2020 Sep 28;32:101128. Epub 2020 Jan 28.

Department of Urology, Oitaken Koseiren, Tsurumi Hospital, Beppu, Oita, Japan.

In the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related adverse events (irAEs). However, the occurrence of hematological irAEs is rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256289PMC
September 2020

The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids.

J Tissue Eng 2020 Jan-Dec;11:2041731420920597. Epub 2020 May 18.

Research Department of Surgical Biotechnology, Division of Surgery & Interventional Science, University College London, London, UK.

Pazopanib is a tyrosine kinase inhibitor used to treat renal cell carcinoma. Few in vitro studies investigate its effects towards cancer cells or endothelial cells in the presence of cancer. We tested the effect of Pazopanib on renal cell carcinoma cells (CAKI-2,786-O) in two-dimensional and three-dimensional tumouroids made of dense extracellular matrix, treated in normoxia and hypoxia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2041731420920597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238304PMC

Laparoscopic nephron-sparing surgery for a tumor near the isthmus of a horseshoe kidney with a complicated blood supply.

J Int Med Res 2020 Jun;48(6):300060520926736

Department of Urology, the Fourth Medical Center of PLA General Hospital, Beijing, China.

A horseshoe kidney is a congenital kidney malformation commonly associated with complications such as hydronephrosis, renal calculi, and infections of the renal pelvis. Renal cell carcinoma is extremely rare in a horseshoe kidney; once it occurs, however, it is intractable because of vascular abnormalities. This is especially true in laparoscopic nephron-sparing surgery, even for tumors of <4 cm in diameter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060520926736DOI Listing

How to obtain a 3D printed model of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE) for surgical simulation (phase I NCT03738488).

Updates Surg 2020 Jun 1. Epub 2020 Jun 1.

Urology and Nephrology Department, Virgen del Rocío University Hospital, Manuel Siurot s/n, Seville, Spain.

This is the phase 1 of a multicenter clinical trial (NCT03738488), which aims to assess the efficacy and efficiency of surgery planning with 3D models of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE) compared to the standard images (CT). The objective of this phase is to obtain a 3D printed model of RCC with VTE that is feasible, accurate, reproducible, suitable for surgical simulation, and affordable. A specific protocol was developed to obtain the computed tomography (CT) image: early arterial and nephrogenic phase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13304-020-00806-6DOI Listing

Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.

Int J Clin Oncol 2020 Jun 2. Epub 2020 Jun 2.

Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Background: Sequential treatment starting with target therapy is still the standard care for metastatic renal cell carcinoma (mRCC), even in the era of immune checkpoint inhibitors. Our objective was to compare the clinical outcomes between axitinib and nivolumab as second-line therapy following prior targeted therapy in mRCC patients.

Methods: We identified 41 patients treated with axitinib and 39 patients treated with nivolumab as a second-line regimen after targeted therapy, and retrospectively compared the treatment efficacy and safety in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-020-01708-8DOI Listing

Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma.

Anticancer Res 2020 Jun;40(6):3485-3489

Department of Urology, Medical School, University of Pecs, Pecs, Hungary

Background/aim: Despite early detection by widespread use of abdominal imaging more than 40% of patients with conventional renal cell carcinoma (RCC) will die due to metastatic disease. Small kinase inhibitors for AXL receptor tyrosine kinase may delay the progression of metastatic cRCC.

Patients And Methods: We analysed AXL expression by immunohistochemistry on tissue multi arrays of 691 conventional RCC without metastasis at the time of nephrectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14335DOI Listing

Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma.

Anticancer Res 2020 Jun;40(6):3119-3128

Department of Urology, University Hospital Bonn, Bonn, Germany.

Background/aim: Myoferlin (MYOF) has emerged as an oncogenic protein in various human cancer types. This study was conducted to investigate comprehensively the expression and functional properties of MYOF in clear-cell renal-cell carcinoma (ccRCC) with respect to its value as diagnostic biomarker and therapeutic target.

Materials And Methods: mRNA and protein expression of MYOF were assessed by quantitative polymerase chain reaction and immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14293DOI Listing

Corrigendum to "Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR) → c-Myc signals" [Cancer Lett. 2015 Nov 1 368(1) 71-78].

Cancer Lett 2020 May 30. Epub 2020 May 30.

George Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA; Sex Hormone Research Center, China Medical University and Hospital, Taichung, 404, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2020.05.017DOI Listing

MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer.

Urol Oncol 2020 May 31. Epub 2020 May 31.

Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA; Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA; Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA. Electronic address:

Patients diagnosed with metastatic renal cell carcinoma (RCC) have ∼12% chance for 5-year survival. The integrity of the extracellular matrix (ECM) that surrounds tumor cells influences their behavior and, when disturbed, it could facilitate local invasion and spread of tumor cells to distant sites. The interplay between von Hippel-Lindau/hypoxia inducible factor signaling axis and activated kinase networks results in aberrant ECM and tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.04.034DOI Listing

MicroRNA-30a-5p: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples.

J Exp Clin Cancer Res 2020 Jun 1;39(1):98. Epub 2020 Jun 1.

Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.

Background: The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers.

Methods: Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-020-01600-3DOI Listing

Axitinib as a third or further line of treatment in renal cancer: a single institution experience.

BMC Urol 2020 Jun 2;20(1):60. Epub 2020 Jun 2.

Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece.

Background: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-020-00618-1DOI Listing

CLN5 in heterozygosis may protect against the development of tumors in a VHL patient.

Orphanet J Rare Dis 2020 Jun 2;15(1):132. Epub 2020 Jun 2.

Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Von Hippel-Lindau syndrome (VHL) is a rare disease of dominant inheritance that increases susceptibility to tumor development, with a complete penetrance at the age of 60. In this report, we present the unprecedented case of a VHL carrier who remains healthy at 72. Under the course of this study, it was discovered that this patient carries a mutation for a second rare disease, Neuronal Ceroid Lipofuscinosis (NCL or CNL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-020-01410-yDOI Listing

[Nasal metastasis from clear cell renal cell carcinoma: report of two cases].

Zhonghua Bing Li Xue Za Zhi 2020 Jun;49(6):642-644

School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20191008-00547DOI Listing

[Clear cell renal cell carcinoma with thyroid metastases: report of three cases].

Authors:
Y Liu Y P Liu

Zhonghua Bing Li Xue Za Zhi 2020 Jun;49(6):636-638

Department of Pathology, Fourth Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050011, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20191105-00714DOI Listing

[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO].

Aktuelle Urol 2020 Jun 2;51(3):236-238. Epub 2020 Jun 2.

Organgruppensprecher der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V., Kuno-Fischer-Str. 8, 14057 Berlin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1079-7621DOI Listing

Thyroid-Like Follicular Carcinoma of the Kidney With Oncocytic Cells: A Case Report and Review of Metastatic and Non-metastatic Tumors.

Int J Surg Pathol 2020 Jun 2:1066896920930283. Epub 2020 Jun 2.

Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Thyroid-like follicular carcinoma of kidney (TLFCK) is a morphological subtype of renal cell carcinoma, which is included as an emerging/provisional entity in the classification of renal tumors, with only about 40 cases reported in literature. It has a distinct histological appearance and immunohistochemical profile as compared with other renal cell cancers. However, these tumors, while appearing distinctive, have not been characterized fully either morphologically or by ancillary techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1066896920930283DOI Listing

[Durable Response after Discontinuation Due to Immune-Related Adverse Events in a Patient with Metastatic Clear Cell Renal Cell Carcinoma : A Case Report].

Hinyokika Kiyo 2020 May;66(5):147-151

The Department of Urology, Sapporo Medical University School of Medicine.

A 70-year-old female with metastatic clear cell renal cell carcinoma was treated with nivolumab. After three dosages, she developed interstitial lung disease which required steroid therapy and nivolumab was discontinued. Thereafter, the target lesion continued to shrinkand the best response was partial response 15 weeks after discontinuation of nivolumab, the reduction rate of which eventually reached 49. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_66_5_147DOI Listing

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Clin Genitourin Cancer 2020 Apr 10. Epub 2020 Apr 10.

Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC. Electronic address:

Background: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of Dako 28-8 and Ventana SP142 assays in mRCC and Dako 22C3 and Ventana SP263 assays in mUC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.03.020DOI Listing

A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.

Clin Genitourin Cancer 2019 Dec 5. Epub 2019 Dec 5.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.

Background: Tyrosine kinase inhibitor-based adjuvant therapy showed no survival benefits for patients with high-risk nonmetastatic renal cell carcinoma (nmRCC). Five randomized immune-oncology checkpoint inhibitor trials are ongoing. We assessed the effect of stage, grade, and histologic type on cancer-specific mortality (CSM) in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials of high-risk nmRCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.010DOI Listing
December 2019

The long noncoding RNA EMBP1 inhibits the tumor suppressor miR-9-5p and promotes renal cell carcinoma tumorigenesis.

Nefrologia 2020 May 29. Epub 2020 May 29.

Department of Gerontology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:

Introduction And Objectives: Long non-coding RNAs (lncRNAs) have garnered interest because of their roles in cancer progression. We aimed to explore the role of the lncRNA embigin pseudogene 1 (EMBP1)-miR-9-5p axis in renal cell carcinoma (RCC).

Materials And Methods: Expression profiling of miR-9-5p and EMBP1 were performed in RCC cell lines and tumor samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2019.12.004DOI Listing

Radiomics Applications in Renal Tumor Assessment: A Comprehensive Review of the Literature.

Cancers (Basel) 2020 May 28;12(6). Epub 2020 May 28.

Department of Urology, Faculty of Medicine, University of Freiburg Medical Centre, 79106 Freiburg, Germany.

Radiomics texture analysis offers objective image information that could otherwise not be obtained by radiologists' subjective radiological interpretation. We investigated radiomics applications in renal tumor assessment and provide a comprehensive review. A detailed search of original articles was performed using the PubMed-MEDLINE database until 20 March 2020 to identify English literature relevant to radiomics applications in renal tumor assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061387DOI Listing

Clinical significance of circulating tumor cells detection in renal cell carcinoma with thrombus: A STROBE-compliant study.

Medicine (Baltimore) 2020 May;99(22):e20615

Department of Urology.

The aim of the study was to evaluate the potential role of circulating tumor cell (CTC) detection in the surgical assessment of renal cell carcinoma (RCC) patients with thrombi.Nine patients diagnosed with renal mass and thrombi were enrolled from June 2018 to January 2019. Blood samples were collected for CTC detection using SE-iFISH assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020615DOI Listing

Identification of biomarkers of clear cell renal cell carcinoma by bioinformatics analysis.

Medicine (Baltimore) 2020 May;99(21):e20470

The Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, PR China.

Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer, and more and more researches find that the occurrence of ccRCC is associated with genetic changes, but the molecular mechanism still remains unclear. The present study aimed to identify aggregation trend of differentially expressed genes (DEGs) in ccRCC, which would be beneficial to the treatment of ccRCC and provide research ideas using a series of bioinformatics approach. Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genomes (KEGG) analysis were used to get the enrichment trend of DEGs of GSE53757 and GSE16449. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020470DOI Listing

The role of COL6A1and PD-1 expressions in renal cell carcinoma.

Turk J Urol 2020 May 27. Epub 2020 May 27.

Department of Urology, Mersin University Medical Faculty.

Objective: The COL6A1 is a gene encoding the alpha 1 polypeptide subunit of collagen 6 (COL6A1), an extracellular matrix protein subunit. Programmed cell death receptor-1 (PD-1) and its ligand, programmed cell death receptor ligand-1 (PD-L1) have been shown to have a prognostic significance in clear cell renal cell carcinomas (RCCs). In this study, we evaluated the expressions of COL6A1 and PD-1 in four different RCC subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tud.2020.20062DOI Listing

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.

Expert Rev Anticancer Ther 2020 Jun 1:1-11. Epub 2020 Jun 1.

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals , Ancona, Italy.

Introduction: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worsening in maximum 3-5 sites while all other tumor sites are controlled by systemic therapy.

Areas Covered: We explore all possible approaches in these settings of patients: the role of local therapies, considering both surgical metastasectomy and/or ablative techniques, the efficacy of systemic therapies and the rationale behind active surveillance. We also discuss ongoing clinical trials in these settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1770601DOI Listing

Differential diagnosis of< 3 cm renal tumorsby ultrasonography: A rapid, Quantitative, Elastography Self-corrected Contrast-enhanced Ultrasound Imaging Mode beyond Screening.

Br J Radiol 2020 Jun 1:20190974. Epub 2020 Jun 1.

Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital & Shanghai Institute of Ultrasound in Medicine, Shanghai, 200233, PR China.

Objectives: To assess the combined diagnostic strategy of contrast-enhanced ultrasound (CEUS) and acoustic radiation force impulse (ARFI) in the precise differential diagnosis of clear cell renal cell carcinoma (CCRCC) and urothelium carcinoma of the renal pelvis (UCRP) with other small renal tumors (SRTs) <3 cm in size.

Methods: The elastography self-corrected CEUS (ESC) mode was established to perform the quantitative differential diagnosis of SRTs (<3 cm). The kidney shear wave velocity (SWV) value recorded by ARFI showed substantial variability in patients with CCRCC (high elasticity value) and UCRP (low elasticity value) compared with other renal masses, thus providing critical self-correction information for the ultrasound differential diagnosis of SRTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20190974DOI Listing

Factors associated with prolonged surgical duration of laparoscopic radical nephrectomy using retroperitoneal approach by non-expert surgeons.

J Nippon Med Sch 2020 May 30. Epub 2020 May 30.

Department of Urology, Nippon Medical School Hospital.

Background: While high body mass index (BMI) and visceral obesity are reportedly associated with a prolonged duration of laparoscopic radical nephrectomy (LRN) via the transperitoneal approach, factors that might prolong the retroperitoneal approach remain unknown. We therefore investigated factors associated with prolonged LRN using a retroperitoneal approach applied by non-expert surgeons.

Methods: We defined surgeons who were not certified to perform laparoscopic surgery by the Japanese Society of Endourology as non-experts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.JNMS.2021_88-302DOI Listing

Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.

Target Oncol 2020 May 30. Epub 2020 May 30.

Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

Background: γ-Glutamyltransferase (GGT) is a marker of oxidative stress. Elevated serum GGT is linked to poor survival in various malignancies; however, there are no data on metastatic renal cell carcinoma (mRCC). Additionally, GGT expression in cancer tissues remains largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-020-00719-9DOI Listing

Soft tissue tumor with novel NR1D1-MAML1 fusion in a pediatric case.

Virchows Arch 2020 May 31. Epub 2020 May 31.

Department of Diagnostic Pathology, Hyogo Cancer Center, 13-70 Kitaooji-cho, Akashi, Hyogo Prefecture, 673-0021, Japan.

We herein describe soft tissue tumor arising in the lower extremity of a pediatric patient. The tumor displayed a unique and wide range of histological features, sheet-like and cohesive growth pattern consisting of enlarged round to epithelioid atypical cells with a large alveolar and pseudopapillary histological architecture, focally mimicking alveolar soft part sarcoma and MiT family translocation renal cell carcinoma. Tumor cells were focally immunoreactive for cytokeratin, S-100, and EMA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-020-02838-0DOI Listing

Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.

Eur J Clin Pharmacol 2020 May 30. Epub 2020 May 30.

Pharmacy Department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

Purpose: The aim of this study was to investigate the impact of acid suppressive therapy on clinical efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma (mRCC).

Methods: A single-center retrospective study was carried out. Charts of mRCC patients who received pazopanib as first-line treatment were reviewed and concomitant use of proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) was studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-020-02902-3DOI Listing

Ambulatory Robotic-Assisted Partial Nephrectomy: Safety and Feasibility Study.

Urology 2020 May 27. Epub 2020 May 27.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Objectives: To evaluate the feasibility and safety of performing Robotic-Assisted Laparoscopic Partial Nephrectomy (RAPN) as outpatient surgery in patients with renal masses.

Methods: We analyzed RAPN performed by a single surgeon at an academic medical center from July 2018 to June 2019 and identified those individual patients who were discharged on the same day. These cases were then compared to a concurrent inpatient RAPN group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.04.111DOI Listing

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.

Invest New Drugs 2020 May 29. Epub 2020 May 29.

Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA, USA.

CDX-014 is an antibody-drug conjugate directed against TIM-1, a surface marker highly expressed in renal cell carcinoma (RCC) and ovarian carcinoma. This phase I, first-in-human trial was conducted to evaluate the safety and preliminary activity of CDX-014 in patients with advanced refractory RCC, following a dose-escalation and dose expansion design. CDX-014 was administered intravenously at doses ranging from 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00945-yDOI Listing

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Nat Med 2020 May 29. Epub 2020 May 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the immunogenomic determinants of the therapeutic response. Although conventional genomic markers (such as tumor mutation burden and neoantigen load) and the degree of CD8 T cell infiltration were not associated with clinical response, we discovered numerous chromosomal alterations associated with response or resistance to PD-1 blockade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0839-yDOI Listing

Ancestry-specific predisposing germline variants in cancer.

Genome Med 2020 May 29;12(1):51. Epub 2020 May 29.

Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Background: Distinct prevalence of inherited genetic predisposition may partially explain the difference of cancer risks across ancestries. Ancestry-specific analyses of germline genomes are required to inform cancer genetic risk and prognosis of diverse populations.

Methods: We conducted analyses using germline and somatic sequencing data generated by The Cancer Genome Atlas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-020-00744-3DOI Listing

Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma.

PLoS One 2020 29;15(5):e0233795. Epub 2020 May 29.

Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Understanding the effects of obesity on the immune profile of renal cell carcinoma (RCC) patients is critical, given the rising use of immunotherapies to treat advanced disease and recent reports of differential cancer immunotherapy outcomes with obesity. Here, we evaluated multiple immune parameters at the genetic, soluble protein, and cellular levels in peripheral blood and renal tumors from treatment-naive clear cell RCC (ccRCC) subjects (n = 69), to better understand the effects of host obesity (Body Mass Index "BMI" ≥ 30 kg/m2) in the absence of immunotherapy. Tumor-free donors (n = 38) with or without obesity were used as controls. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233795PLOS

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

JAMA Oncol 2020 May 29. Epub 2020 May 29.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Importance: Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge in mRCC is unknown.

Objective: To evaluate the safety and efficacy of ICI rechallenge in patients with mRCC.

Design, Setting, And Participants: This multicenter, retrospective cohort study included consecutive patients with mRCC from 9 institutions in the US who received at least 2 separate lines of ICI (ICI-1, ICI-2) between January 2012 and December 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2169DOI Listing

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.

JAMA Oncol 2020 May 29. Epub 2020 May 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Importance: Papillary renal cell carcinoma (PRCC) is the most common type of non-clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, volitinib), a highly selective MET-tyrosine kinase inhibitor, demonstrated antitumor activity in this patient group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2218DOI Listing